This regulatory-friendly media is developed through Metabolic Pathway Design approach to increase process yields in the manufacture of monoclonal antibodies (MAbs) for therapeutic use using a variety of cholesterol auxotrophic NS0 cell clones.
HyClone CDM4NS0 Media requires no cholesterol or GS supplementation, as the media has sufficient amounts to support NS0 cell culture already in the formulation.
CDM4NS0 Media has been successfully tested in a variety of culture systems, including T-flasks, shaker flasks, and bioreactors using batch and fed-batch strategies.